FAQ

How concerned should we be about the new VoC?

WHO declares a variant as a VoC after assessment when there is increase in transmissibility or detrimental change in COVID-19 epidemiology; OR increase in virulence or change in clinical disease presentation; OR decrease in effectiveness of public health and social measures or available diagnostics, vaccines, therapeutics. (Source: WHO)

It is important to highlight that Omicron has been declared VoC based on the observed mutations, their predicted features of increased transmission and immune evasion, and preliminary evidence of detrimental change in COVID-19 epidemiology, such as increased reinfections. The definitive evidence for increased remission and immune evasion is awaited.

What precautions should we take?

The precautions and steps to be taken remain same as before. It is essential to mask yourself properly, take both doses of vaccines (if not yet vaccinated), maintain social distancing and maintain good ventilation to the maximum possible.

Will there be a third wave?

Omicron cases are increasingly being reported from countries outside of South Africa and given its characteristics, it is likely to spread to more countries including India. However, the scale and magnitude of rise in cases and most importantly the severity of disease that will be caused is still not clear. Further, given the fast pace of vaccination in India and high exposure to delta variant as evidenced by high seropositivity, the severity of the disease is anticipated to be low. However, scientific evidence is still evolving.

Will the existing vaccines work against Omicron?

While, there is no evidence to suggest that existing vaccines do not work on Omicron, some of the mutations reported on Spike gene may decrease the efficacy of existing vaccines. However, vaccine protection is also by antibodies as well as by cellular immunity, which is expected to be relatively better preserved. Hence vaccines are expected to still offer protection against severe disease and, vaccination with the available vaccines is crucial. If eligible, but not vaccinated, one should get vaccinated.

How is India responding?

Indian government is monitoring the situation closely and is issuing suitable guidelines from time to time. Meanwhile, the scientific and medical community is geared up for developing and deploying diagnostics, carrying out genomic surveillance, generating evidence about viral and epidemiologic characteristics, and development of therapeutics.

Why do variants occur?

Variants are normal part of evolution and as long as the virus is able to infect, replicate and transmit, they will continue to evolve. Further, not all variants are dangerous and most often than not, we don’t notice them. Only when they are more infectious, or can reinfect people they gain prominence. The most important step to avoid generation of variants is to reduce the number of infections.

What is TKDL?

The Traditional Knowledge Digital Library (TKDL) is a pioneering initiative of India, under the joint collaboration of the Council of Scientific and Industrial Research (CSIR) and Ministry of Ayurveda, Yoga & Naturopathy, Unani, Siddha, Sowa Rigpa and Homoeopathy (AYUSH), to prevent exploitation and to protect Indian traditional knowledge at Patent Offices worldwide. The TKDL was set up with due approvals of the Cabinet Committee on Economic Affairs in 2001.
The TKDL includes India’s rich traditional knowledge related to the systems of medicine from classical/ traditional books related to Ayurveda, Unani, Siddha and Sowa Rigpa as well as practices of Yoga. The information from the ancient texts of medicine and health existing in local languages such as Sanskrit, Hindi, Arabic, Persian, Urdu, Tamil, Bhoti, etc. have been digitized in five international languages, namely, English, French, German, Spanish and Japanese in the TKDL database as prior art. The database currently contains more than 4.2 lakh formulations/ practices transcribed from texts of Ayurveda, Unani, Siddha, Sowa Rigpa and Yoga.
As per the extant approvals of the Cabinet Committee on Economic Affairs in place, the access of the database is given to patent offices world-wide that have signed non-disclosure access agreements with the CSIR. Thirteen patent offices including the Indian Patent Office (Controller General of Patents, Designs & Trade Marks), European Patent Office, US Patent Office, Japanese Patent Office, German Patent Office, Canadian Patent Office, Chile Patent Office, Australian Patent Office, UK Patent Office, Malaysian Patent Office, Russian Patent Office, Peru Patent Office, and Spanish Patent & Trademark Office have been granted access to the TKDL database.
The CSIR-TKDL Unit also files third party observations and pre-grant oppositions on patent applications related to India’s traditional knowledge based on the TKDL evidences. So far, 241 patent applications have been either withdrawn/deemed withdrawn or amended or set aside on the basis of TKDL evidence thus protecting Indian traditional knowledge.
More details of TKDL can be accessed at: http://www.tkdl.res.in

What was the second battle of Haldighati in which CSIR was involved?

The “second battle of Haldighati,” is what the media dubbed a pioneering case in a "rule-based" war in the context of what India felt was a wrongly granted US patent on the use of turmeric for wound healing. The rule is that the applicant has a right to patent innovations only after demonstrating the novelty, non-obviousness and usefulness of an article. The use of turmeric for wound healing is not novel because it is a part of India’s prior knowledge as recorded in ancient Sanskrit and Pali texts and formal papers in journals such as The Indian Journal of Medical Research, etc. CSIR followed the recognized legal procedures and proved to the US Patent Office that such use of turmeric in wound healing was clearly the consequence of prior knowledge. The US Patent Office scrapped revoked the patent and India won that particular battle.